Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.82 |
| ▸ | GAK | O14976 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | MET | P08581 | 2/20 | 0.75 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.75 |
| ▸ | BLK | P51451 | 2/20 | 0.75 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.75 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.75 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.75 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.75 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 0.75 |
| ▸ | CIT | O14578 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623503 | 1.00 | EGFR (0.82) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL185736 | 1.00 | EGFR (0.82) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3588596 | 0.97 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3581137 | 0.97 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3581135 | 0.97 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3588595 | 0.97 | EGFR (0.80) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3581642 | 0.96 | EGFR (0.79) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3581638 | 0.96 | EGFR (0.79) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL1191414 | 0.95 | EGFR (0.81) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL3577826 | 0.94 | EGFR (0.73) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-12-20 | — | — | US | claimed |
| US-20170112835-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2017-04-27 | — | — | US | claimed |
| WO-2016025641-A1 | COMBINATIONS OF AN ERK INHIBITOR AND AN EGFR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-1731511-B1 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-12 | — | — | EP | claimed |
| EP-1345910-B9 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-06-04 | — | — | EP | claimed |
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | claimed |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | claimed |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | claimed |
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | claimed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-28 | — | — | US | claimed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306072-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885GAK 699/4885 |
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885GAK 708/4885 |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885GAK 794/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | EGFR 218/4885ERBB2 109/4885GAK 688/4885 |
| US-20050165013-A1 | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, CHRM2 | EGFR 2/4885ERBB2 4/4885GAK 123/4885 |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | EGFR 52/4885ERBB2 96/4885GAK 299/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885GAK 586/4885 |
| US-20170112835-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885GAK 708/4885 |
| US-20100144639-A1 | USE OF INHIBITORS OF THE EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) / PROSTATIC HYPERTROPHY | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885GAK 1408/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | EGFR 43/4885ERBB2 75/4885GAK 436/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885GAK 1286/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | EGFR 3691/4885ERBB2 2317/4885GAK 4053/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885GAK 1408/4885 |
| US-20040048887-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | CHRM3, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885GAK 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.